Australian patients disadvantaged for access to new prescription medicines


Medicines Australia has just released the COMPARE report, which analyses access to innovative medicines by Australian patients. Unfortunately for our patients, Australia’s regulatory and reimbursement processes create an environment that limits access to new drugs.

According to the report, Australia ranks 18th in a list of OECD countries for reimbursement of first-in-class registered in those countries in the years 2009-2014.  Critically for cancer patients, there is an average period of 29 months between regulatory approval and reimbursement for new oncology drugs, compared to an average of 19 months for the OECD average.  During this period, although these drugs can be prescribed, they are only accessible to those people who have sufficient resources to pay for new treatments out of their own pocket.

The full report can be downloaded from: